docetaxel

P3, N=446, Recruiting, Shanghai Miracogen Inc. | Not yet recruiting --> Recruiting

Available therapeutic options include radioligand therapy (e.g. lutetium-177-PSMA-617), cabazitaxel, PARP inhibitors (particularly for patients with DNA repair gene alterations), second-line ARTAs, further chemotherapy and immunotherapeutic approaches. Finally, the review provides an overview of promising emerging therapies poised to expand the treatment landscape for mCRPC. These include bispecific T cell engagers, androgen receptor degraders, and antibody-drug conjugates, which are currently under investigation in clinical trials and may soon offer new avenues for treatment beyond traditional mechanisms.

In contrast, it spared non-tumorigenic prostate epithelial cells (PCS-440-010), unlike Docetaxel...Western blot analysis revealed no change in the caspase-8 expression, but a marked upregulation of Beclin-1, probably related to autophagy cell death pathways. These findings highlight the selective cytotoxicity and anti-metastatic potential of Pllans-II, positioning it as a promising prototype for the development of novel therapeutic strategies against prostate cancer.

Postoperatively, the patient received TC(docetaxel+cyclophosphamide) chemotherapy, total breast irradiation, and tamoxifen for 10 years. Considering the different subtypes and absence of other lesions, the patient was considered to have latent breast cancer as a new lesion. Chemotherapy, including anti- HER2 therapy, radiotherapy, and endocrine therapy, was administered as adjuvant treatment.

The patient received 6 courses of adjuvant chemotherapy with docetaxel and carboplatin. No recurrence has been detected during 3 years and 9 months of postoperative follow-up. This case may provide valuable insight into the diagnosis and multidisciplinary management of this uncommon disease.

At the time of tracheotomy, biopsy evaluation revealed that the metastatic left supraclavicular lymph nodes were ER- and HER2-positive; therefore, the treatment was switched to a trastuzumab, pertuzumab, and docetaxel(TPD)combination for HER2-positive recurrent breast cancer. However, PET-CT revealed increased accumulation in the recurrent lesions, and the treatment was switched to trastuzumab deruxtecan (T-DXd). The accumulation of recurrent foci became less pronounced and the patient continued to progress without further deterioration.

P1/2, N=45, Active, not recruiting, iOnctura | Recruiting --> Active, not recruiting

SNHG12 knockdown inhibits DTX resistance of PCa cells by reducing SNHG12 binding to ELAVL1 to inhibit the activation the PI3K/AKT signaling pathway.

This work introduces a first-in-class therapeutic approach that overcomes long-standing barriers to drugging survivin, offering a new avenue for combating docetaxel-resistant metastatic CRPC. With robust efficacy, a favorable safety profile, and potential for clinical translation, 7I10 and 7I14 represent significant advancements in the development of targeted cancer therapies to overcome docetaxel resistance.

P=N/A, N=1600, Not yet recruiting, Bayer

P2, N=100, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting

P3, N=85, Not yet recruiting, Relmada Therapeutics, Inc.